MELISSA KRZUS: Open Payments
NPI 1205243524 · DYER, IN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,094 in 44 payments from 23 companies in 2025. Trend: 2023 $1,099 · 2024 $1,706 · 2025 $1,094
Food & beverage: $1,094
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 5 | $117 |
| Novartis Pharmaceuticals Corporation | 4 | $113 |
| Stryker Corporation | 2 | $102 |
| Celgene Corporation | 3 | $80 |
| Astellas Pharma US Inc | 3 | $69 |
| E.R. Squibb & Sons, L.L.C. | 3 | $66 |
| Merck Sharp & Dohme LLC | 3 | $64 |
| Daiichi Sankyo Inc. | 2 | $53 |
| Exelixis Inc. | 2 | $51 |
| Janssen Biotech, Inc. | 2 | $43 |
Products named: KISQALI, AUGMENT INJECTABLE, REBLOZYL, Xtandi, CABOMETYX, OPDIVO, RYBREVANT, VENCLEXTA.
Industry payments across IN — which companies pay providers there.
